NCT03866395

Effects of Ivabradine on Residual Myocardial Ischemia After PCI

Effects of Ivabradine on Residual Myocardial Ischemia After PCI Evaluated by Stress Echocardiography

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Azienda Policlinico Umberto I · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized pharmacological study evaluating the effects of ivabradine in patients with residual angina after PCI. The role of ivabradine in patients with angina, without systolic dysfunction, is not yet clear. The investigators performed in all patients an echostress to evaluate the effects of therapy with ivabradine after 30 days in terms of exercise tolerance and diastolic function.

Detailed description

BACKGROUND. Residual angina after PCI is a frequently-occurring disease. Ivabradine improves symptoms but its role in patients without left-ventricular systolic dysfunction is still unclear. The aim was to quantify the effects of ivabradine in terms of MVO2 indicators and diastolic function. METHODS. 28 consecutive patients with residual angina after PCI were randomized to ivabradine 5 mg twice/day(IG) or standard therapy(CG). All patients performed a stress echocardiography at the enrollment and after 30 days. Myocardial oxygen consumption was estimated from: double product(DP); triple product(TP) integrating DP with ejection-time(ET). Diastolic function was evaluated determining E and A waves, E' measurements and E/E' ratio both at rest and at the peak of exercise.

Conditions

• Angina Pectoris, Stable

Interventions

Type	Name	Description
DRUG	Ivabradine	Ivabradine 5 mg twice a day

Timeline

• Start date: 2015-03-05
• Primary completion: 2017-03-07
• Completion: 2017-03-07
• First posted: 2019-03-07
• Last updated: 2019-03-07

Locations

1 site across 1 country: Italy